This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Camurus AB.
Reference
Phillips-Jackson H, et al. Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements. ClinicoEconomics and Outcomes Research : 6 May 2020. Available from: URL: https://doi.org/10.2147/CEOR.S242984
Rights and permissions
About this article
Cite this article
Use of injectable buprenorphine cuts cost for care in opioid-use disorder. PharmacoEcon Outcomes News 853, 31 (2020). https://doi.org/10.1007/s40274-020-6826-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6826-1